L-methylfolate
ApprovedSmall molecule
L-methylfolate is one of 48 small molecule programs targeting Major Depressive Episode. It is currently in Approved.
2
Indications
3
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
82 competitors in Generalized Anxiety Disorder
#DrugCompanyPhaseTrials
1Brintellix
TakedaPhase 3
Viibryd
AbbViePhase 3
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
PD 0360324
PfizerPhase 3
Risperdal
WWim Janssens
Phase 3
Effexor
WWyeth-Lederle Vaccines
Phase 3
Quetiapine XR
AstraZenecaPhase 3
Lu AF95245
LundbeckPhase 3
Vraylar
AbbViePhase 2
L-methylfolate
MMassachusetts General Hospital
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Generalized Anxiety Disorder1 trial
Major Depressive Episode1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for L-methylfolate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMassachusetts General Hospital